Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis
Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis
复制标题
DOI：
10.2147/ijgm.s236166
复制
发表时间：
2019-12
影响因子：
2.3
通讯作者：
Y. Yamanaka;Yusuke Sawai;S. Nomura
中科院分区：
文献类型：
--
作者：
Y. Yamanaka;Yusuke Sawai;S. Nomura
背景：最终导致血管并发症的血小板衍生微粒(PDMP)可能被用作评估血栓形成区域的工具。我们将PDMPs、高迁移率族蛋白-1(HMGB1)和可溶性内皮蛋白C受体(SEPCR)作为预测癌症相关血栓形成(CAT)的有用预后指标，以评价PDMPs在癌症患者中的应用价值。方法对232例癌症患者进行调查，其中24例(10.3%)在初诊后6个月内出现血栓并发症。采用酶联免疫吸附试验检测PDMP和生物标志物水平。结果肿瘤患者的PDMPs、HMGB1和sEPCR值均高于对照组。特别是，肺癌患者的这些水平与对照组相比显著升高，CAT阳性患者的这些水平都高于CAT阴性患者。特别是，CAT阳性患者的PDMP水平显著高于CAT阴性患者。与以前的数据相比，首次检查后存活超过901天的患者的PDMP水平显著降低。PDMP水平与HMGB1呈正相关，并在体外用健康人富含血小板的血浆引起PDMPs的剂量依赖性升高。结论肿瘤患者PDMP和HMGB1水平的联合升高可能与CAT有关。因此，凝血功能障碍可能是由于这些生物标志物水平升高而导致的，并导致癌症患者预后不良。
Background Platelet-derived microparticles (PDMPs) that ultimately cause vascular complications might be used as a tool to assess thrombotic areas. We identified PDMPs, high-mobility group box-1 (HMGB1) and soluble endothelial protein C receptor (sEPCR) as useful prognosis indicators for cancer-related thrombosis (CAT) to evaluate the utility of PDMPs in cancer patients. Methods We investigated 232 cancer patients: 24 (10.3%) had thrombotic complications within 6 months after their first examination. Levels of PDMP and biomarkers were measured by enzyme-linked immunosorbent assay. Results The levels of PDMPs, HMGB1 and sEPCR were higher in cancer patients compared with controls. In particular, these levels were significantly elevated in lung cancer patients compared with controls, and all were higher in CAT-positive patients compared with CAT-negative patients. In particular, PDMP levels in CAT-positive patients were significantly elevated compared with CAT-negative patients. PDMP levels were significantly lower in patients who lived for more than 901 days after their first examination compared with previous data. PDMP levels were positively correlated with HMGB1, and caused the dose-dependent elevation of PDMPs in vitro using platelet-rich plasma from healthy persons. Conclusion The combined increase in PDMP and HMGB1 levels might be related to CAT in cancer patients. Therefore, coagulatory dysfunction may result from increased levels of these biomarkers and contribute to the poor prognosis of cancer patients.